pharmaphorum |
Novo Nordisk's diabetes pill clears cardiac safety hurdle
pharmaphorum Novo Nordisk is set to file its daily semaglutide type 2 diabetes pill after it cleared a phase 3 trial assessing its cardiac safety, with results showing it also reduced risk of cardiovascular and all-causes death in high-risk patients. The active ... |
from diabetes - Google News
Social Plugin